Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAA) is a blank-check company formed to pursue a merger or acquisition target in the domestic pharmaceutical manufacturing sector, reflecting the broader policy and industry push to reshore drug production to the United States. The company remains in its search phase as of its most recent quarterly filing, a Form 10-Q submitted to the SEC on August 14, 2026 under accession number 0001213900-26-090035. DMAA's sector focus positions it within the healthcare and life-sciences SPAC universe at a time of heightened legislative and investor interest in domestic pharmaceutical supply chains. For the full DMAA deal timeline, management backgrounds, warrant terms, and comparable transaction data, create a free account on SpacDesk.